Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30007993HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30010715HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30007994HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30013874HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30003287HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053658HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053659HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053660HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053661HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053662HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TCGA Plot Options
Drug Information
GeneTOP1
DrugBank IDDB14962
Drug NameTrastuzumab deruxtecan
Target IDBE0000971
UniProt IDP11387
Regulation Typeinhibitor
PubMed IDs31047803
CitationsTamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL